Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
EMXC vs IBB: how they differ
EMXC and IBB hold 0% of their weight in the same names, and EMXC returned more over the year.
iShares MSCI Emerging Markets ex China ETF and iShares Biotechnology ETF.
What they hold in common
By the books each fund has filed, EMXC and IBB hold 0% of their money in the same securities at the same weight.
| Only in EMXC | Only in IBB |
|---|---|
| Taiwan Semiconductor Manufacturing Compa 17.97% | Vertex Pharmaceuticals, Inc. 8.09% |
| SK hynix Inc. 8.37% | Amgen, Inc. 7.84% |
| MediaTek Inc. 2.04% | Gilead Sciences, Inc. 6.85% |
| DELTA ELECTRONICS, INC. 1.47% | Regeneron Pharmaceuticals, Inc. 4.91% |
| HON HAI PRECISION INDUSTRY CO., LTD. 1.13% | Argenx SE 3.76% |
| Samsung Electronics Co., Ltd. 1.07% | Alnylam Pharmaceuticals, Inc. 3.12% |
| HDFC BANK LIMITED 0.88% | Natera, Inc. 2.89% |
| RELIANCE INDUSTRIES LIMITED 0.83% | Revolution Medicines, Inc. 2.78% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and May 31, 2026.
| EMXC iShares MSCI Emerging Markets ex China ETF | IBB iShares Biotechnology ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | iShares | iShares |
| What it is | MSCI Emerging Markets ex China | Biotechnology |
| Total return, 1 year | +55.5% | +41.5% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +38.0 pts | +24.0 pts |
| Expense ratio | 0.25% | 0.44% |
| Already in the S&P 500 | 0.0% | 35.6% |
| Holdings | 662 | 248 |
EMXC in plain words
EMXC is an index equity fund tracking the MSCI Emerging Markets ex China. Over the year to Sep 11, 2026 it returned +55.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.25% a year. By its holdings filed for May 31, 2026, 0% of the fund by weight is stocks the S&P 500 also holds, across 662 positions, with the top ten at 44.3%. It sat 5.5% below its high of Jun 22, 2026 on Sep 11, 2026.
IBB in plain words
IBB is an index equity fund tracking the Biotechnology. Over the year to Sep 11, 2026 it returned +41.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.44% a year. By its holdings filed for Jun 30, 2026, 36% of the fund by weight is stocks the S&P 500 also holds, across 248 positions, with the top ten at 44.8%. It sat 6.5% below its high of Aug 19, 2026 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, EMXC or IBB?
- In the year to Sep 12, 2026, with distributions reinvested, EMXC returned +55.5% and IBB returned +41.5%, so EMXC returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, EMXC or IBB?
- EMXC charges 0.25% a year and IBB charges 0.44%, so EMXC is cheaper. Fees come from each fund's prospectus.
- How much do EMXC and IBB overlap with the S&P 500?
- By their latest filed holdings, 0% of EMXC and 36% of IBB by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, EMXC against IBB, data as of Sep 12, 2026. https://etfiq.com/compare/any/EMXC-IBB Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources